Zogenix, Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that they have signed a non-binding letter of intent for an exclusive co-marketing and technology development option agreement with Battelle to advance the development and commercialization of Zogenix’s DosePro® drug. Battelle, one of the world’s largest independent research and development organizations, will work with Zogenix to offer DosePro needle-free drug delivery technology to pharmaceutical and biotechnology firms for new commercial out-licensing opportunities.
Zogenix’s DosePro patented technology, which has United States and Europe regulatory approvals, enables needle-free medication delivery under the skin by using a small amount of compressed gas to deliver a liquid version of medication through the skin. It is the only commercially available, single-use, disposable, needle-free, subcutaneous delivery technology in the world.
“We recognize that DosePro can provide sustainable competitive advantages for many injectable drugs, especially biologics. With Battelle’s expertise in product development and strong relationships with biopharmaceutical companies, we can now match DosePro technology to drug candidates in a more efficient manner by providing customizable drug delivery solutions that can effectively deliver biologics, vaccines and other critical drugs. We believe this arrangement will accelerate entry into licensing agreements with major pharmaceutical companies,” said John Turanin, Vice President and General Manager, DosePro Technology, Zogenix in a press release.
The intent of this partnership is to help meet the needs of biopharmaceutical companies that want to offer more customizable platform technologies that create different products for increased efficacy, patient compliance and market share. Zogenix has completed prototype design for the product but hopes that further development in collaboration with Battelle will help to broaden the capability of the technology to deliver larger dose volumes, which are required for high-dose biological products.
“We believe DosePro features market-leading technology for the safe and effective delivery of biologics, especially high viscosity formulations, which is critically important to our customers. This collaboration will enhance our ability to extend our leadership in drug delivery technology development to create innovative solutions for the pharmaceutical industry,” said Barbara Kunz, President, Battelle Health and Life Sciences Global Business in the press statement.
For more information on Zogenix, visit www.zogenix.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
